DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Bausch - 2 Jim Cramer's - 2 Jim Cramer - 2 Jim - 2 we've - 1 Salix - 1 companywide EBITDA - 1 Rafael Henrique - 1
Top related locs:
BLCO Bausch New York U.S Interphex
Top related orgs:
Pharmaceuticals - 2 Norwich Pharmaceuticals - 2 Bausch Health - 2 Management - 2 CNBC - 2 Health Companies - 1 U.S . - 1 Appeals - 1

Search resuls for: "companywide EBITDA"


2 mentions found


☆ Strong earnings results at Bausch Health once again overshadowed by legal battle
  + stars: | 2024-02-22 | by ( Zev Fima | ) www.cnbc.com   time to read: +4 min
Bausch Health Companies reported a fourth-quarter earnings beat on Tuesday. However , the stock's upside is likely limited until the legal battle over one of its most popular drugs is resolved. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $869 million was up 5.6% versus last year and ahead of the $863 billion consensus estimate. That makes Xifaxan responsible for 38% of Bausch Health sales, excluding B+L. Breaking that down, $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb.
Persons: we've, Bausch, Salix, companywide EBITDA, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health Companies, Pharmaceuticals, Norwich Pharmaceuticals, U.S ., Appeals, Federal Circuit, Bausch Health, Management, CNBC Locations: BLCO, Bausch
☆ Bausch Health's decent quarter can't overcome headwind of ongoing patent dispute
  + stars: | 2023-11-02 | by ( Zev Fima | ) www.cnbc.com   time to read: +4 min
But they aren't enough to overcome the headwind of the company's ongoing patent legislation. Good numbers, but they take a back seat to the legal battle over Bausch drug Xifaxan. Management didn't provide any update on timing for when the remaining 88% of BLCO that Bausch Health owns will be sold off. Management now expects companywide EBITDA in a range of $3.01 to $3.11 billion, versus an earlier range of $3.0 to $3.15 billion. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Bausch, Xifaxan, BCH's Bausch, companywide, Jim Cramer's, Jim Cramer, Jim, Timothy Fadek Organizations: Health, Revenue, Pharmaceuticals, Norwich Pharmaceuticals, D.C, Norwich, FDA, XIFAXAN, Management didn't, Bausch Health, Management, CNBC, International Pharmaceutical, Bloomberg, Getty Images Bloomberg, Getty Locations: New York, U.S, Interphex
0 next >>
Total: 2